Ünal, İ. Et Al. 2023. Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson's disease model in zebrafish; mechanism involving ketogenesis and autophagy.. Brain research , vol.1820, no.1 , 148536.

Ünal, İ., Cansız, D., Beler, M., Sezer, Z., Güzel, E., & Alturfan, E. I., (2023). Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson's disease model in zebrafish; mechanism involving ketogenesis and autophagy.. Brain research , vol.1820, no.1, 148536.

Ünal, İsmail Et Al. "Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson's disease model in zebrafish; mechanism involving ketogenesis and autophagy.," Brain research , vol.1820, no.1, 148536, 2023

Ünal, İsmail Et Al. "Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson's disease model in zebrafish; mechanism involving ketogenesis and autophagy.." Brain research , vol.1820, no.1, pp.148536, 2023

Ünal, İ. Et Al. (2023) . "Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson's disease model in zebrafish; mechanism involving ketogenesis and autophagy.." Brain research , vol.1820, no.1, p.148536.

@article{article, author={İsmail Ünal Et Al. }, title={Sodium-dependent glucose co-transporter-2 inhibitor empagliflozin exerts neuroprotective effects in rotenone-induced Parkinson's disease model in zebrafish; mechanism involving ketogenesis and autophagy.}, journal={Brain research}, year=2023, pages={148536} }